Rhythm Biosciences Ltd. (AU:RHY)

ASX:RHY

RHY

Rhythm Biosciences Ltd.

RESEARCH TOOLSreports

Want to see AU:RHY full AI Analyst Report?

Rhythm Biosciences Ltd. (RHY) Price & Analysis

Q: What was Rhythm Biosciences Ltd.’s price range in the past 12 months?

Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.

Q: What is Rhythm Biosciences Ltd.’s market cap?

Rhythm Biosciences Ltd.’s market cap is AU$41.87M.

Q: When is Rhythm Biosciences Ltd.’s upcoming earnings report date?

Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 83 days.

Q: How were Rhythm Biosciences Ltd.’s earnings last quarter?

Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.

Q: Is Rhythm Biosciences Ltd. overvalued?

According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Rhythm Biosciences Ltd. pay dividends?

Rhythm Biosciences Ltd. does not currently pay dividends.

Q: What is Rhythm Biosciences Ltd.’s EPS estimate?

Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Rhythm Biosciences Ltd. have?

Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.

Q: What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?

Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.

Q: Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?

Currently, no hedge funds are holding shares in AU:RHY

12 Followers

RHY Stock Chart & Stats

AU$0.14

<AU$0.01(1.16%)

At close: Jan 09 4:00 PM EST

AU$0.14

<AU$0.01(1.16%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.28

Previous CloseN/A

Volume786.78K

Average Volume (3M)462.98K

Market Cap

AU$41.87M

Enterprise ValueAU$41.08M

Total Cash (Recent Filing)AU$1.73M

Total Debt (Recent Filing)AU$262.44K

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding364,059,840

10 Day Avg. Volume510,821

30 Day Avg. Volume462,976

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)22.03

Price to Sales (P/S)4.56

P/FCF Ratio-4.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clear Product Focus On Blood‑based Colorectal Cancer ScreeningRhythm’s concentrated R&D on a blood-based colorectal cancer screening test targets a persistent, large clinical need for noninvasive early detection. A single, well-defined product strategy improves chances of regulatory clarity, focused clinical validation, and easier commercialization or licensing discussions with healthcare systems.

High Gross Margin And Improving Free Cash Flow TrendReported high gross margins imply the core test economics could scale favorably once volumes increase, and an improving free cash flow trend shows progress toward cash generation. Together these durable characteristics support long‑term unit economics and improve attractiveness to partners or payors once commercial rollout begins.

Lean Organizational Structure (small Team)A small, focused team suggests low fixed overhead and nimble decision‑making, important for an early‑stage diagnostics company. Lean operations can stretch runway while completing clinical validation and regulatory work, and enable rapid pivoting of development priorities with limited incremental cost.

Bears Say

Sharp Recent Revenue DeclineA 42.9% revenue drop signals weak commercial traction or one‑time setbacks that undermine sustainable growth. For a company dependent on progressing from development to routine testing, falling revenues reduce reinvestment capacity, strain credibility with payors/partners, and increase the need for external financing.

Persistent Negative Profitability (net, EBIT, EBITDA)Ongoing negative margins reflect structural gaps between operating costs and current revenue generation. Sustained unprofitability limits internal financing for trials, commercialization, and scale-up, raising dilution risk or forcing unfavorable partnerships unless material revenue or cost improvement occurs.

High Leverage And Negative Operating Cash FlowA debt/equity ratio of 1.68 combined with negative operating cash flow constrains financial flexibility. High leverage increases refinancing and covenant risk, while persistent negative OCF shortens runway absent new capital or rapid commercial uptake, limiting ability to fund regulatory/commercial milestones.

Rhythm Biosciences Ltd. News

Rhythm Biosciences Frames ASX Position While Emphasising Limits of Investor Presentation

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has released an investor...

1d ago

RHY

Rhythm Biosciences expands ColoSTAT access program as clinician uptake grows

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an update. Rhythm Biosciences has expanded its ColoSTAT Clinical Access...

10d ago

RHY

Rhythm Biosciences’ ColoSTAT Test Gains Early Clinical Traction in Underserved CRC Patients

An announcement from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences reported early clinical adoption...

1M ago

RHY

Rhythm Biosciences Schedules Investor Webinar to Update on Cancer Diagnostics Progress

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an announcement. Rhythm Biosciences will host an investor webinar on...

1M ago

RHY

Rhythm Biosciences Cuts Underwritten Options Proceeds After Administrative Error

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an update. Rhythm Biosciences has revised the final proceeds from...

1M ago

RHY

Rhythm Biosciences Seeks ASX Quotation for New Options

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences has applied to the ASX for...

2M ago

RHY

Rhythm Biosciences Issues New Shares and Confirms Regulatory Compliance

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has issued 18,834,007 ordinary...

2M ago

RHY

Rhythm Biosciences Seeks ASX Quotation for 18.8 Million New Shares

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has applied to the...

2M ago

RHY

Rhythm Biosciences clarifies ASX query on underwriting agreement and disclosure gaps

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has responded to an...

2M ago

RHY

Rhythm Biosciences Raises $5.5m to Accelerate ColoSTAT and geneType Sales

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences has completed the successful exercise and...

2M ago

RHY

RHY FAQ

What was Rhythm Biosciences Ltd.’s price range in the past 12 months?

Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.

What is Rhythm Biosciences Ltd.’s market cap?

Rhythm Biosciences Ltd.’s market cap is AU$41.87M.

When is Rhythm Biosciences Ltd.’s upcoming earnings report date?

Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 83 days.

How were Rhythm Biosciences Ltd.’s earnings last quarter?

Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.

Is Rhythm Biosciences Ltd. overvalued?

According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rhythm Biosciences Ltd. pay dividends?

Rhythm Biosciences Ltd. does not currently pay dividends.

What is Rhythm Biosciences Ltd.’s EPS estimate?

Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rhythm Biosciences Ltd. have?

Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.

What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?

Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.

Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?

Currently, no hedge funds are holding shares in AU:RHY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rhythm Biosciences Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-476.27%

Trailing 12-Months

Asset Growth

-47.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Biosciences Ltd.

Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.